Making Motion: (:), Cardinal Financial (NASDAQ:CFNL), Huttig Building Products (NASDAQ:HBP), Everest Re (NYSE:RE), Progenics Pharmaceuticals (NASDAQ:PGNX), Tesaro (NASDAQ:TSRO)

Cardinal Financial Corp. (NASDAQ:CFNL) shares advanced 0.40% in last trading session and ended the day at $22.69. Its has a return on assets of 1.40%. Cardinal Financial Corp. (NASDAQ:CFNL) quarterly performance is 6.44%.

Cardinal Financial Corporation is a financial holding company. The Company, through its subsidiary, Cardinal Bank (the Bank), offers traditional bank loan and deposit products and services to both commercial and retail customers with 32 banking offices located in Northern Virginia, Maryland and the greater Washington, District of Columbia metropolitan area.

Cardinal Bank (NASDAQ: CFNL) is pleased to announce that Anamika Chauhanhas joined the company as Vice President, Manager of Cardinal Bank’s Tysons Corner Banking Office. Chauhan will oversee the new client acquisition efforts and daily operations of the Tysons Corner office located at 1750 Tysons Boulevard.

Huttig Building Products Inc. (NASDAQ:HBP) ended the last trading day at $3.14. Company weekly volatility is calculated as 2.52% and price to cash ratio as 31.24. Huttig Building Products Inc. (NASDAQ:HBP) showed a weekly performance of -0.32%.

BHP Billiton PLC (BHP) is an Australia-based mining company having interests in diversified natural resources. The Company mines, extracts and produce aluminium, coal, copper, iron ore, manganese, nickel, silver and uranium, and oil and gas. The Company extracts and process minerals, and oil and gas from its production operations located primarily in Australia, the Americas and Southern Africa.

Huttig Building Products, Inc. reports preliminary financial results for the quarter ended June 30, 2015. Revenues of USD 175.10 million, Net Earnings of USD 5.20 million, and Earnings per Share (EPS) of USD 0.20.
Gross margins widened from 19.86% to 20.33% compared to the same quarter last year, operating (EBITDA) margins now 3.66% from 2.85%.

On 11 September, Everest Re Group Ltd. (NYSE:RE) shares advanced 0.58% and was closed at $177.25. RE EPS growth in last 5 year was 14.40%. Everest Re Group Ltd. (NYSE:RE) year to date (YTD) performance is 5.75%.

Everest Re Group, Ltd. (Group), through its subsidiaries, is engaged in the underwriting of reinsurance and insurance in the United States, Bermuda and international markets. The Company underwrites reinsurance both through brokers and directly with ceding companies. The Company underwrites insurance principally through general agent relationships, brokers and surplus lines brokers.

Everest Re Group Ltd. (NYSE:RE) announced that Lloyds Franchise Board has provided its “in principle” approval for the creation of Everest Syndicate 2786.The new syndicate will be managed under a turnkey arrangement by Asta Managing Agency Ltd (Asta), an established and well respected third-party provider of key management services to start-up syndicates. Everest and Asta are working to secure the final approvals to commence underwriting business incepting January 1, 2016.

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares advanced 3.09% in last trading session and ended the day at $7.34. PGNX Gross Margin is 99.10% and its has a return on assets of -11.20%. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) quarterly performance is 10.88%.

Progenics Pharmaceuticals, Inc.is engaged in developing medicines for oncology. The Company completed Phase II clinical trials of two product candidates for prostate cancer, and resumed a pivotal Phase II trial of an ultra-orphan radiotherapy candidate for pheochromocytoma. Its principal clinical-stage product candidates in oncology are PSMA ADC, 1404 (trofolastat) and Azedra.

Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) nnounced that the U.S. Food and Drug Administration (FDA) has accepted for review Valeant’s New Drug Application for RELISTOR® (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) action date of April 19, 2016.

Tesaro, Inc. (NASDAQ:TSRO) caters to the Healthcare space. Its weekly performance is 3.68%. On the last day of trading company shares ended up $55.00. Tesaro, Inc. (NASDAQ:TSRO) distance from 50-day simple moving average (SMA50) is -1.16%.

TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011.

Tesaro Inc., a Waltham-based oncology-focused biopharmaceutical company, announced that the U.S. Food and Drug Administration’s approval of Varubi. Varubi, also known as rolapitant, in combination with other antiemetic agents is used in prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy including, but not limited to, highly emetogenic chemotherapy in adults.